1-propanol has been researched along with Hyperlipoproteinemia Type II in 12 studies
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.
propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atorvastatin is an HMG-CoA reductase inhibitor which across its dosage range (10-80 mg/day) has shown significantly greater lipid-lowering effects than all previously marketed statins." | 2.71 | Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. ( Alvarez, E; Castaño, G; Fernández, L; Illnait, J; Lezcay, M; Mas, R; Mesa, M, 2003) |
| " The dosage was doubled to 10 mg/day if total cholesterol values were > 6." | 2.70 | Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. ( Castaño, G; Fernández, JC; Fernández, L; Illnait, J; López, E; Más, R, 2002) |
| " After this period, dosage was doubled to 5 mg twice-a-day for the next 8 weeks and then again doubled to 10 mg twice-a-day." | 2.67 | Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. ( Fernández, JC; Fernández, L; Illnait, J; Más, R; Pons, P; Robaina, C; Rodríguez, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castaño, G | 7 |
| Mas, R | 10 |
| Fernández, L | 10 |
| Illnait, J | 8 |
| Mesa, M | 3 |
| Alvarez, E | 3 |
| Lezcay, M | 1 |
| Pepping, J | 1 |
| Gámez, R | 3 |
| Mendoza, S | 3 |
| Fernández, J | 3 |
| Greyling, A | 1 |
| De Witt, C | 1 |
| Oosthuizen, W | 1 |
| Jerling, JC | 1 |
| Pons, P | 1 |
| Rodríguez, M | 1 |
| Robaina, C | 1 |
| Fernández, JC | 3 |
| Canetti, M | 1 |
| Moreira, M | 1 |
| Diaz, E | 1 |
| Arruzazabala, ML | 1 |
| Molina, V | 1 |
| Carbajal, D | 1 |
| Valdés, S | 1 |
| Alcocer, L | 1 |
| Campos, E | 1 |
| López, LE | 1 |
| López, E | 1 |
1 review available for 1-propanol and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Policosanol.
Topics: Aged; Algorithms; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2 | 2003 |
11 trials available for 1-propanol and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Chol | 2003 |
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; | 2005 |
A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; | 2005 |
Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Dietary Su | 2006 |
Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Drug Tolerance; Fatty Acids; Fatty Alcoh | 1994 |
A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyp | 1995 |
Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Topics: Adenosine Diphosphate; Anticholesteremic Agents; Arachidonic Acid; Collagen; Double-Blind Method; Fa | 1998 |
A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyperlipoprotei | 1999 |
Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Fatty Alcoh | 2000 |
Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Fatty Alcohols; Female | 2001 |
Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Double-Blind Method; Fatty Alcohols; Female; Human | 2002 |